Mehr als ein Expektorans: neue wissenschaftliche Daten zu Ambroxol im Kontext der Behandlung bronchopulmonaler Erkrankungen

Abstract

Ambroxol is still intensively researched. The traditional indication as an expectorant is confirmed. But there is also an ever better understanding of the various mechanisms of action as well as the ever more exact modeling of the structures under investigation. New fields of application are conceivable, e. g. in patients with severe pulmonary disease who undergo surgery or who are in intensive care, as an adjuvant in anti-infective therapies, especially in infections with biofilm-producing pathogens, or in rare diseases such as lysosomal storage diseases. However, final evidence of the clinical relevance in these fields of application is still missing.

Potential new treatment strategies for COVID-19: is there a role for bromhexine as add-on therapy?

“…The available data suggest further that ambroxol is a potent inducer of surfactant synthesis in AT2 cells [63][64][65]. Its lung protective properties have been discussed in infants and severely ill adult patients as well as the potential as an adjuvant in anti-infective therapy [64]. Thus, bromhexine also provides indirect protective effects.…”

Ambroxol snižuje frekvenci kašle (během dne i v noci), a tím zlepšuje schopnost soustředění a kvalitu života

“…Ambroxol zmírňuje příznaky kašle při akutních respiračních infekcích díky svým sekretolytickým, protizánětlivým, antioxidativním, antibakteriálním, antivirálním a lokálním anestetickým účinkům. Dále byla pozornost rovněž věnována imunomodulačním vlastnostem [2].…”

L'ambroxolo riduce la frequenza della tosse (giorno e notte), favorendo così la capacità di concentrazione e migliorando la qualità della vita

“…L'ambroxolo allevia i sintomi della tosse in presenza di infezioni respiratorie acute grazie al suo effetto secretolitico, antinfiammatorio, antiossidante, antibatterico, antivirale e anestetico locale. Si è discusso anche delle sue proprietà immunomodulanti [2].…”

“…Il sondaggio, condotto in 126 farmacie, ha posto l'attenzione sull' efficacia dell'ambroxolo in quattro diverse formulazioni (pastiglie molli, capsule a rilascio prolungato, sciroppo per la tosse per pazienti adulti e sciroppo per la tosse per pazienti pediatrici) in pazienti con profili diversi [2]. A 965 clienti è stato chiesto di completare un questionario dopo l'acquisto.…”